Singapore: SHARE digital portal launched for medical devices

In brief

On 21 May 2025, the Health Sciences Authority (HSA) conducted an industry briefing to provide updates on the implementation of the Singapore Health Product Access and Regulatory e-System (SHARE) for medical devices. The session highlighted key changes implemented for medical devices on SHARE, the user interface, and key features available on SHARE. SHARE will be launched from 14 July 2025.


Contents

In more detail

SHARE is a digital platform developed by the HSA to streamline regulatory submissions. It will replace the existing Medical Device Information Communication System (MEDICS) and provide a unified and integrated platform for regulators, businesses, industry partners, and the general public to collaborate and manage product lifecycle activities more efficiently. Our previous client alert on SHARE may be found here.

In an industry briefing on 21 May 2025, the HSA outlined several key changes to SHARE aimed at streamlining regulatory processes and improving user experience:

1. Independent product notifications: Class A product notifications can now be submitted independently in SHARE, as opposed to being bundled within dealer license applications or amendments via a single Excel sheet in MEDICS.

2. Third party access: Applicants can now directly request third party access for queries raised through SHARE, eliminating the need for separate HSA pin authorization requests.

3. Importer assignment: Importers under a different UEN must now acknowledge and accept tagging assignments by registrant directly, with no requirement to assign authorized wholesalers for the device listing.

4. Export certificates: Applications can be submitted directly in SHARE without prior export notifications.

5. Fulfilment of Approval conditions (FoAC): Company users can track their approval conditions and submit FoAC applications directly through SHARE, with new automated reminders sent as the due date approaches.

6. Auto-retention: For companies with GIRO arrangements, auto-retention of product listings will now be triggered 30 days before the due date, compared to one day after in MEDICS.

7. Future-dated cancellations: Applicants can now define future effective dates for cancellations, compared to immediate cancellation upon approval in MEDICS.

8. Flexible payment options: Online payments for new product registrations will now be triggered at these timepoints: application fee upon submission and evaluation fee upon confirmation of the evaluation route. This aligns with triggers for payment via GIRO. Companies with GIRO arrangements can now choose their preferred payment mode at the point of submission.

From 14 July 2025, companies may access SHARE with their CorpPass.

* * * * *

LOGO_Wong&Leow_Singapore

© 2025 Baker & McKenzie. Wong & Leow. All rights reserved. Baker & McKenzie. Wong & Leow is incorporated with limited liability and is a member firm of Baker & McKenzie International, a global law firm with member law firms around the world. In accordance with the common terminology used in professional service organizations, reference to a "principal" means a person who is a partner, or equivalent, in such a law firm. Similarly, reference to an "office" means an office of any such law firm. This may qualify as "Attorney Advertising" requiring notice in some jurisdictions. Prior results do not guarantee a similar outcome.

Contact Information

Copyright © 2025 Baker & McKenzie. All rights reserved. Ownership: This documentation and content (Content) is a proprietary resource owned exclusively by Baker McKenzie (meaning Baker & McKenzie International and its member firms). The Content is protected under international copyright conventions. Use of this Content does not of itself create a contractual relationship, nor any attorney/client relationship, between Baker McKenzie and any person. Non-reliance and exclusion: All Content is for informational purposes only and may not reflect the most current legal and regulatory developments. All summaries of the laws, regulations and practice are subject to change. The Content is not offered as legal or professional advice for any specific matter. It is not intended to be a substitute for reference to (and compliance with) the detailed provisions of applicable laws, rules, regulations or forms. Legal advice should always be sought before taking any action or refraining from taking any action based on any Content. Baker McKenzie and the editors and the contributing authors do not guarantee the accuracy of the Content and expressly disclaim any and all liability to any person in respect of the consequences of anything done or permitted to be done or omitted to be done wholly or partly in reliance upon the whole or any part of the Content. The Content may contain links to external websites and external websites may link to the Content. Baker McKenzie is not responsible for the content or operation of any such external sites and disclaims all liability, howsoever occurring, in respect of the content or operation of any such external websites. Attorney Advertising: This Content may qualify as “Attorney Advertising” requiring notice in some jurisdictions. To the extent that this Content may qualify as Attorney Advertising, PRIOR RESULTS DO NOT GUARANTEE A SIMILAR OUTCOME. Reproduction: Reproduction of reasonable portions of the Content is permitted provided that (i) such reproductions are made available free of charge and for non-commercial purposes, (ii) such reproductions are properly attributed to Baker McKenzie, (iii) the portion of the Content being reproduced is not altered or made available in a manner that modifies the Content or presents the Content being reproduced in a false light and (iv) notice is made to the disclaimers included on the Content. The permission to re-copy does not allow for incorporation of any substantial portion of the Content in any work or publication, whether in hard copy, electronic or any other form or for commercial purposes.